Cytiva and the life sciences business of Pall Corp. have completed their integration as one business under the Cytiva brand. With nearly 16,000 associates in 40 countries, the new Cytiva supports customers in solving major biotechnology challenges to help advance and accelerate therapeutics. 
 
In January 2023, the life sciences business of Pall separated from Pall Corp. Pall’s biotech portfolio is now a product family in Cytiva’s bioprocess business. The Pall medical portfolio will remain a market brand and part of Cytiva. Pall Corp. continues to operate as a Danaher operating company serving customers across a wide range of industrial applications. 

Cytiva’s expanded portfolio to accelerate therapeutics from discovery to delivery now includes product brands: Allegro, Supor, iCELLis, Kleenpak, and Pegasus, in addition to ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex, and Xuri.
 
Emmanuel Ligner, Danaher Group Executive, President and CEO of Cytiva, said, “The biotechnology industry is at the start of a new era. New modalities are emerging, there is greater emphasis on local manufacturing, and we are accelerating the adoption of digital solutions. Our customers need a partner that can meet them at every part of their process. Uniting Cytiva and the life sciences business of Pall gives us the focus, expertise, and talent to help our customers discover, develop, and deliver the next generation of novel therapeutics.”